Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in pulmonary metastatic osteosarcoma
NCT03811886Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of natalizumab in osteosarcoma (OS), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Dose Limiting Toxicity at 30 days. Planned start Dec 2024; status: withdrawn.
02
Drugs
natalizumab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03811886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811886.